ABSTRACT Salicylate (SAL) has been recently implicated in the antidiabetic effect in humans. We assessed whether 5′-AMP-activated protein kinase (AMPK) in skeletal muscle is involved in the effect of SAL on glucose homeostasis. Rat fast-twitch epitrochlearis and slow-twitch soleus muscles were incubated in buffer containing SAL. Intracellular concentrations of SAL increased rapidly (<5 min) in both skeletal muscles, and the Thr 172 phosphorylation of the α subunit of AMPK increased in a dose-and time-dependent manner. SAL increased both AMPKα1 and AMPKα2 activities. These increases in enzyme activity were accompanied by an increase in the activity of 3-O-methyl-D-glucose transport, and decreases in ATP, phosphocreatine, and glycogen contents. SAL did not change the phosphorylation of insulin receptor signaling including insulin receptor substrate 1, Akt, and p70 ribosomal protein S6 kinase. These results suggest that SAL may be transported into skeletal muscle and may stimulate AMPK and glucose transport via energy deprivation in multiple muscle types. Skeletal muscle AMPK might be part of the mechanism responsible for the metabolic improvement induced by SAL.
Introduction
Salicylate (SAL), a willow bark product, has been used as an anti-inflammatory agent since ancient times. SAL induces systemic anti-inflammatory effects by suppressing cyclooxygenase, resulting in decreased production of proinflammatory mediators such as prostaglandins [1] .
Interestingly, a number of clinical studies have suggested that SAL stimulates metabolic processes and improves glucose homeostasis in humans.
Goldfine et al [2] demonstrated that a 14-week oral SAL treatment (salsalate 3.0-4.0 g/day) significantly improved glycemic control in patients with type 2 diabetes (T2D). The mean changes in the hemoglobin A1c level were −0.36% at 3.0 g/day, −0.34% at 3.5 g/day, and −0.49% at 4.0 g/day compared with the placebo. More recently, Goldfine et al [3] demonstrated that long-term (48 weeks) oral SAL treatment (salsalate 3.5 g/day) significantly improved glycemic control in people with T2D. The mean hemoglobin A1c level after 48 weeks was 0.37% lower in the SAL group than in the placebo group.
We hypothesized that 5′-AMP-activated protein kinase (AMPK) in skeletal muscle plays a pivotal role in the antidiabetic effect of SAL. AMPK is a metabolite-sensing protein kinase and is acutely activated by energy-depriving stimuli in skeletal muscle such as exercise (contraction).
Although Hawley et al [4] first reported that AMPK is phosphorylated in mouse soleus muscle 90 min after an intraperitoneal injection of SAL, to our 4 knowledge, no study has provide fundamental evidence of AMPK activation in skeletal muscle. Thus, the primary aim of the current study was to determine whether SAL is taken up into skeletal muscle cells and, if so, whether it stimulates AMPK by altering the energy status. We examined two different types of isolated rat skeletal muscles: fast-glycolytic epitrochlearis [5] and slow-oxidative soleus muscles [6] . 5 
Materials and Methods

Animals
Male Sprague Dawley rats weighing 150 g (Shimizu Breeding
Laboratories, Kyoto, Japan) fed a standard chow and water ad libitum were randomly divided into experimental groups after an overnight fast. The experimental protocols were approved by Kyoto University Graduate School of Human and Environmental Studies, and Kyoto University Radioisotope Research Center.
Muscle preparation in vitro
Muscle incubation was conducted as we have previously described [7] .
Epitrochlearis and soleus muscles were isolated after cervical dislocation.
The muscles were attached to an incubation apparatus and preincubated in Krebs-Ringer bicarbonate buffer (KRB) containing 2 mM pyruvate for 40 min. 
Western blotting
Western blot analysis was performed as we have previously described [7] .
Frozen muscle was homogenized in buffer containing 1% Triton X-100, 20 developed using enhanced chemiluminescence (Millipore) and detected with ImageCapture G3 (Liponics, Tokyo, Japan).
2.4. Isoform-specific AMPK activity assay AMPK comprises the catalytic α and regulatory β and γ subunits, and there are two distinct α subunits: α1 and α2 [8] . The kinase activities of α1-containing AMPK complex (AMPKα1) and α2-containing AMPK complex (AMPKα2) were measured as we have previously described [7] . Frozen muscles were homogenized in Buffer A, and the resultant supernatants (100 µg protein) were incubated with either anti-α1 or -α2 antibody [7] and min, and the radioactivity in the supernatant was measured by a scintillation counter. The intracellular space was determined as described [9] , and the intracellular SAL concentration was calculated. 3-O-Methyl-D-glucose (3MG) transport was measured using the double-isotope ([ 3 H]3MG and D-[1-14 C]mannitol) method, as we have previously described [7] . The transport activity was expressed as 3MG taken up per intracellular space per hour.
2.6. ATP, phosphocreatine (PCr), and glycogen assay ATP and PCr contents were measured enzymatically as we have described previously [10] . Glycogen content was measured using a glucose assay reagent (Glucose CII Test , Wako, Osaka, Japan) as we have previously described [11] .
Statistical analysis
Data are expressed as mean ± standard error (SE). Differences between two groups were compared with Student's t test. Multiple means were analyzed using one-way ANOVA followed by post hoc comparison with Tukey's or Dunnett's test. P < 0.05 was considered significant. The Thr 172 residue of the α subunit is the stimulatory phosphorylation site of AMPK [12] . We examined the phosphorylation status in both muscles. (Fig. 1C) .
SAL uptake in skeletal muscles
To our knowledge, no study has shown that SAL is taken up into skeletal muscle tissue. We found that the intracellular concentration of SAL increased rapidly in both epitrochlearis and soleus muscles in a time-dependent manner ( Fig. 2A) . The intracellular concentration of SAL was 3.1 ± 0.2 mM in epitrochlearis and 1.8 ± 0.1 mM in soleus at 15 min after 10 the start of exposure to buffer containing 5 mM SAL.
3.3. Effects of SAL on glucose transport and energy status in skeletal muscles AMPK is thought to act as a signaling molecule leading to an increase in insulin-independent glucose transport elicited by energy-depriving stresses in skeletal muscle [13, 14] . The increased AMPK activity by SAL (5 mM, 30 min) was associated with a 2.7-fold increase in 3MG transport in epitrochlearis muscle and a 4.2-fold increase in soleus muscle (Fig. 2B) compared with the basal conditions. Correspondingly, the contents of ATP, PCr, and glycogen were significantly lower in SAL-treated muscle samples than in the basal muscle samples for both epitrochlearis and soleus (Table 1) .
Effects of SAL on insulin signaling molecules in skeletal muscles
The pharmacological inhibitor of oxidative phosphorylation, DNP, significantly phosphorylated AMPK in both muscles (Fig. 2C) . The AMPK activator AICAR strongly phosphorylated AMPK in epitrochlearis and slightly phosphorylated AMPK in soleus, as we have previously reported [15] .
By contrast, insulin did not phosphorylate AMPK in either muscle. Similar to DNP and AICAR, SAL did not increase the phosphorylation of insulin signaling molecules including IRS1, Akt, and p70S6K. SAL did not affect GLUT4 or actin content in either muscle. [18, 20, 21] . In our earlier studies, we demonstrated that Morus alba leaf extract [22] , caffeine [10] , berberine [15] , Coptidis rhizoma extract [23] , and caffeic acid [24] , all of which have been implicated as having antidiabetic properties, acutely (<30 min) promoted AMPK activity in isolated rat skeletal muscles.
SAL has been shown to uncouple oxidative phosphorylation [1, 25] . The SAL-induced decrease in ATP concentration has been documented in Drosophila melanogaster tissue culture (SL2) cells [26] and human neutrophils [27] . However, as far as we know, the present study is the first to demonstrate the ability of SAL to decrease the energy status in skeletal muscle. Interestingly, Hawley et al [4] showed that SAL is a direct AMPK activator that binds to the same site as the synthetic AMPK activator A-769662, which causes allosteric AMPK activation and inhibition of 12 dephosphorylation of the α subunit Thr 172 . They also demonstrated that SAL promoted AMPK phosphorylation and activity in the absence of energy deprivation (an increase in ADP: ATP ratio) in HEK-293 cells [4] . Thus, SAL may stimulate AMPK via both energy-dependent and energy-independent processes in skeletal muscle.
Hawley et al [4] found that oral SAL treatment for 2 weeks decreased fasting glucose concentration and improved insulin sensitivity and glucose tolerance in both the wild-type and AMPK β1 subunit knockout mice in a high fat diet-induced insulin-resistant condition. This seems to suggest that the effect of SAL on glucose metabolism is AMPK independent. However, Western blot analysis of rat tissues has revealed that the β1 subunit is most abundant in the liver and that little exists in skeletal muscle, whereas the β2 subunit is most abundant in skeletal muscle and little exists in the liver [28] In fact, the β1-knockout mice had decreased AMPK activity in the liver but not in skeletal muscle [29] . Therefore, it is still possible that skeletal muscle AMPK plays an important role in mediating the effects of SAL on glucose homeostasis.
The typical plasma concentration of SAL for clinical use is 0.95-1.9 mM, but the plasma concentration of free SAL falls in the range of <0.25 mM because of plasma protein binding of 80-90% [1] . Although we showed that the intracellular concentration of SAL increased rapidly after exposure to SAL ( Fig. 2A) , it is unlikely that a single oral dose of SAL is enough to induce substantial metabolic activation in skeletal muscle. As speculated from the 13 finding of Goldfine et al [2] who demonstrated improved glycemic control after a 14-week SAL treatment in people with T2D, repeated SAL administration might contribute to a clinically relevant activation of AMPK in skeletal muscle.
An advantage of using an isolated muscle preparation is that we could eliminate the confounding effects elicited by systemic administration of SAL.
In particular, we considered the possibility that SAL inhibits IKKβ, an enzyme that is responsible for the activation of nuclear factor κ [30] , and that evokes direct and/or indirect metabolic changes in skeletal muscle [31] . We used Western blotting to examine the inhibitory effect of SAL on IKKα/β phosphorylation in isolated muscles. However, because of the very low phosphorylation in the basal samples, we could not determine whether IKK phosphorylation decreased after SAL treatment in either muscle (data not shown).
In summary, we report here for the first time that SAL was transported into muscle cells, where it increased both AMPKα1 and α2 activities, and glucose transport, and decreased muscle energy status. These effects occurred in both fast-and slow-twitch skeletal muscles. We propose that skeletal muscle AMPK is involved in the mechanism leading to the SAL-induced activation of glucose metabolism. 
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